Myocardial revascularization in patients with coronary heart disease and type 2 diabetes
Abstract
The review discusses myocardial revascularization in patients with coronary heart disease and type 2 diabetes. The data presented include findings from recent research and international and national recommendations and provides evidence on the advantages of coronary artery bypass surgery over percutaneous coronary intervention for patients with diabetes mellitus, stable coronary artery disease and multiple coronary artery lesions. Type 2 diabetes remains a significant predictor of adverse long-term outcomes of coronary artery bypass surgery. Therefore, we review studies showing that different strategies of coronary revascularization and preoperative preparation can affect the results of coronary intervention in patients with diabetes.
About the Authors
Natalya A. Bezdenezhnykh
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
MD, PhD
Competing Interests: No conflict of interests
Russian Federation
MD, PhD
Competing Interests: No conflict of interests
Aleksey N. Sumin
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
MD, PhD
Competing Interests: Авторы декларируют отсутствие конфликта интересов
Russian Federation
MD, PhD
Competing Interests: Авторы декларируют отсутствие конфликта интересов
References
1. Authors/Task Force M, Ryden L, Grant PJ, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035-3087. doi: 10.1093/eurheartj/eht108
2. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999-3054. doi: 10.1093/eurheartj/ehr236
3. Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation--mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol. 2012;32(8):1771-1776. doi: 10.1161/ATVBAHA.111.241869
4. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318-1327. doi: 10.1016/j.jacc.2009.10.061
5. Сумин А.Н., Безденежных Н.А., Безденежных А.В., и др. Факторы риска больших сердечно-сосудистых событий в отдаленном периоде коронарного шунтирования у пациентов с ишемической болезнью сердца при наличии сахарного диабета 2 типа. // Российский кардиологический журнал. – 2015. – Т. 6. – №122 – С. 30-37. [Sumin AN, Bezdenezhnykh NA, Bezdenezhnyh AV,et al. Risk Factors major cardiovascular events in the long term coronary artery bypass grafting in patients with coronary heart disease in the presence of type 2 diabetes. Russian Journal of Cardiology. 2015;6(122):30-37 (In Russ.)].
6. Koskinas KC, Siontis GC, Piccolo R, et al. Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients. Circ Cardiovasc Interv. 2016;9(2):e003255. doi: 10.1161/CIRCINTERVENTIONS.115.003255
7. Каретникова В.Н., Беленькова Ю.А., Зыков М.В., и др. Уровень гликемии как маркер прогноза у больных инфарктом миокарда с подъемом сегмента ST. // Кардиология. – 2012. – Т. 52. -№1. – С. 26–31. [Karetnikova VN, Belenkova YA, Zykov MV, et al. Glucose level as a marker of prognosis in patients with myocardial infarction with ST-segment elevation. Cardiology. 2012;52(1):26-31(In Russ)].
8. Каретникова В.Н., Барбараш О.Л., Квиткова Л.В., и др. Раннее выявление нарушений углеводного метаболизма – важный маркер отдаленного прогноза при инфаркте миокарда. // Патология кровообращения и кардиохирургия. – 2010. – №2. – С.33. [Karetnikova VN, Barbarash OL, Kvitkova LV, et al. Early detection disorders of carbohydrate metabolism – important marker long-term prognosis of myocardial infarction. Pathology of the circulatory and cardiac surgery. 2010;(2):33. (In Russ)].
9. Барбараш О.Л., Груздева О.В., Акбашева О.Е., и др. Биохимические показатели, ассоциированные с развитием сахарного диабета через год после перенесенного инфаркта миокарда. // Клиническая медицина. – 2014. – Т. 92. – №11 – С. 52-59. [Barbarash OL, Gruzdeva OV, Akbasheva OE, et al. Biochemical parameters associated with the development of diabetes mellitus one year after myocardial infarction. Clinical Medicine. 2014;92(11):52-59 (In Russ)].
10. Standards of Medical Care in Diabetes—2016: Summary of Revisions. Diabetes Care. 2016;39(Supplement 1):S4-S5. doi: 10.2337/dc16-S003
11. O’Donoghue ML, Vaidya A, Afsal R, et al. An Invasive or Conservative Strategy in Patients With Diabetes Mellitus and Non–ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2012;60(2):106-111. doi: 10.1016/j.jacc.2012.02.059
12. Koskinas KC, Siontis GC, Piccolo R, et al. Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients. Circ Cardiovasc Interv. 2016;9(2):e003255. doi: 10.1161/CIRCINTERVENTIONS.115.003255
13. Дедов И.И., Терёхин С.А. Реваскуляризация миокарда у больных сахарным диабетом // Сахарный диабет. – 2010. – Т. 13. – №4 – C. 18-23. [Dedov II, Terekhin SA. Myocardial revascularization in diabetic patients. Diabetes mellitus. 2010;13(4):18-23. (In Russ)]. doi: 10.14341/2072-0351-6052
14. Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск) // Сахарный диабет. – 2015. – Т. 18. – №1S – C. 1-112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). Diabetes mellitus. 2015;18(1S):1-112.] doi: 10.14341/DM20151S1-112
15. Сумин А.Н., Безденежных Н.А., Безденежных А.В., и др. Влияние сахарного диабета 2 типа и мультифокального атеросклероза на ближайшие исходы операции коронарного шунтирования. // Кардиология и сердечно-сосудистая хирургия. – 2011. – Т. 2. – С. 13-19. [Sumin AN, Bezdenezhnykh NA, Bezdenezhnykh AV, et al. The effect of type 2 diabetes and multifocal atherosclerosis on the outcome of the next coronary bypass surgery. Cardiology and Cardiovascular Surgery. 2011;2:13-19 (In Russ)].
16. Bundhun PK, Wu ZJ, Chen MH. Coronary artery bypass surgery compared with percutaneous coronary interventions in patients with insulin-treated type 2 diabetes mellitus: a systematic review and meta-analysis of 6 randomized controlled trials. Cardiovasc Diabetol. 2016;15:2. doi: 10.1186/s12933-015-0323-z
17. Holzmann MJ, Rathsman B, Eliasson B, et al. Long-term prognosis in patients with type 1 and 2 diabetes mellitus after coronary artery bypass grafting. J Am Coll Cardiol. 2015;65(16):1644-1652. doi: 10.1016/j.jacc.2015.02.052
18. Luthra S, Leiva-Juarez MM, Taggart DP. Systematic Review of Therapies for Stable Coronary Artery Disease in Diabetic Patients. Ann Thorac Surg. 2015;100(6):2383-2397. doi: 10.1016/j.athoracsur.2015.07.005
19. Giustino G, Dangas GD. Surgical Revascularization versus Percutaneous Coronary Intervention and Optimal Medical Therapy in Diabetic Patients with Multi-Vessel Coronary Artery Disease. Prog Cardiovasc Dis. 2015;58(3):306-315. doi: 10.1016/j.pcad.2015.08.005
20. Kaul U, Bangalore S, Seth A, et al. Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes. N Engl J Med. 2015;373(18):1709-1719. doi: 10.1056/NEJMoa1510188
21. Bangalore S, Toklu B, Feit F. Outcomes with coronary artery bypass graft surgery versus percutaneous coronary intervention for patients with diabetes mellitus: can newer generation drug-eluting stents bridge the gap? Circ Cardiovasc Interv. 2014;7(4):518-525. doi: 10.1161/CIRCINTERVENTIONS.114.001346
22. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375-2384. doi: 10.1056/NEJMoa1211585
23. Lee BJ, Herbison P, Wong CK et al. Is the advantage of coronary bypass graft surgery over percutaneous coronary intervention in diabetic patients with severe multivessel disease influenced by the status of insulin requirement? J Geriatr Cardiol. 2014;11(1): 83-89.
24. Hakeem A, Garg N, Bhatti S, et al. Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data. J Am Heart Assoc. 2013;2(4):e000354. doi: 10.1161/JAHA.113.000354
25. Lim JY, Deo SV, Kim WS, et al. Drug-eluting stents versus coronary artery bypass grafting in diabetic patients with multi-vessel disease: a meta-analysis. Heart Lung Circ. 2014;23(8):717-725. doi: 10.1016/j.hlc.2014.02.005
26. Wu YC, Su TW, Zhang JF, et al. Coronary artery bypass grafting versus drug-eluting stents in patients with severe coronary artery disease and diabetes mellitus: systematic review and meta-analysis. J Diabetes. 2015;7(2):192-201. doi: 10.1111/1753-0407.12176
27. Shaw LJ, Cerqueira MD, Brooks MM, et al. Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. J Nucl Cardiol. 2012;19(4):658-669. doi: 10.1007/s12350-012-9548-3
28. Brooks MM, Chaitman BR, Nesto RW, et al. Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2012;126(17):2115-2124. doi: 10.1161/CIRCULATIONAHA.112.092973
29. Deb S, Wijeysundera HC, Ko DT, et al. Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review. JAMA. 2013;310(19):2086-2095. doi: 10.1001/jama.2013.281718
30. Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541-2619. doi: 10.1093/eurheartj/ehu278
31. Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. Eur Heart J. 2011;32(22):2748-2757. doi: 10.1093/eurheartj/ehr305
32. Zhang X, Wu Z, Peng X, et al. Prognosis of diabetic patients undergoing coronary artery bypass surgery compared with nondiabetics: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2011;25(2):288-298. doi: 10.1053/j.jvca.2010.09.021
33. Zhang H, Yuan X, Osnabrugge RL, et al. Influence of diabetes mellitus on long-term clinical and economic outcomes after coronary artery bypass grafting. Ann Thorac Surg. 2014;97(6):2073-2079. doi: 10.1016/j.athoracsur.2014.02.047
34. Cумин А.Н., Безденежных Н.А., Безденежных А.В., и др. Факторы, ассоциированные с госпитальной летальностью при коронарном шунтировании у пациентов с ишемической болезнью сердца в сочетании с сахарным диабетом 2 типание факторов, влияющих на исходы КШ у данных пациентов // Сахарный диабет. – 2014. – Т. 17. – №4 – C. 25-34. [Sumin AN, Bezdenezhnykh NA, Bezdenezhnykh AV, et al. Factors associated with in-hospital mortality after coronary artery bypass grafting in patients with CHD and type 2 diabetes. Diabetes mellitus. 2014;17(4):25-34. (In Russ)]. doi: 10.14341/DM2014425-34
35. Сумин А.Н., Безденежных Н.А., Иванов С.В., и др. К вопросу о риске послеоперационных осложнений коронарного шунтирования у пациентов с сахарным диабетом 2 типа. // Бюллетень Научного центра сердечно-сосудистой хирургии им. А.Н. Бакулева РАМН «Сердечно-сосудистые заболевания». – 2012. – Т. 13. – №5 – С. 59-68. [Sumin AN, Bezdenezhnyh NA, Ivanov SV, et al. On the issue of the risk of postoperative complications of coronary artery bypass grafting in patients with type 2 diabetes. The Bulletin of A.N. Bakoulev Scientific Center for Cardiovascular Surgery of Russian Academy of Medical Sciences «CARDIOVASCULAR DISEASES». 2012;13(5):59-68. (In Russ)].
36. Gatti G, Dell’Angela L, Maschietto L, et al. The Impact of Diabetes on Early Outcomes after Routine Bilateral Internal Thoracic Artery Grafting. Heart Lung Circ. 2016;25(8):862-869. doi: 10.1016/j.hlc.2016.02.009
37. Raza S, Sabik JF, 3rd, Ainkaran P, Blackstone EH. Coronary artery bypass grafting in diabetics: A growing health care cost crisis. J Thorac Cardiovasc Surg. 2015;150(2):304-302 e302. doi: 10.1016/j.jtcvs.2015.03.041
38. Kinoshita T, Asai T, Suzuki T, et al. Preoperative hemoglobin A1c predicts atrial fibrillation after off-pump coronary bypass surgery. Eur J Cardiothorac Surg. 2012;41(1):102-107. doi: 10.1016/j.ejcts.2011.04.011
39. Surer S, Seren M, Saydam O, et al. The relationship between HbA1c & atrial fibrillation after off-pump coronary artery bypass surgery in diabetic patients. Pak J Med Sci. 2016;32(1):59-64. doi: 10.12669/pjms.321.8588
40. Ujueta F, Weiss EN, Sedlis SP, Shah B. Glycemic Control in Coronary Revascularization. Curr Treat Options Cardiovasc Med. 2016;18(2):12. doi: 10.1007/s11936-015-0434-6
41. Onorati F, Rubino AS, Cuda A, et al. Impact of endothelial activation on infective and inflammatory complications after cardiac surgery in type II diabetes mellitus. Int J Artif Organs. 2011;34(6):469-480. doi: 10.5301/IJAO.2011.8329
42. Masoumi G, Frasatkhish R, Bigdelian H, et al. Insulin infusion on postoperative complications of coronary artery bypass graft in patients with diabetes mellitus. Res Cardiovasc Med. 2014;3(2):e17861. doi: 10.5812/cardiovascmed.17861
43. Umpierrez G, Cardona S, Pasquel F, et al. Randomized Controlled Trial of Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery: GLUCO-CABG Trial. Diabetes Care. 2015;38(9):1665-1672. doi: 10.2337/dc15-0303
44. Kuhl J, Sartipy U, Eliasson B, et al. Relationship between preoperative hemoglobin A1c levels and long-term mortality after coronary artery bypass grafting in patients with type 2 diabetes mellitus. Int J Cardiol. 2016;202:291-296. doi: 10.1016/j.ijcard.2015.09.008
45. Harskamp RE, Brennan JM, Xian Y, et al. Practice patterns and clinical outcomes after hybrid coronary revascularization in the United States: an analysis from the society of thoracic surgeons adult cardiac database. Circulation. 2014;130(11):872-879. doi: 10.1161/CIRCULATIONAHA.114.009479
46. Anastasiadis K, Antonitsis P, Haidich AB, et al. Use of minimal extracorporeal circulation improves outcome after heart surgery; a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2013;164(2):158-169. doi: 10.1016/j.ijcard.2012.01.020
47. Kajimoto K, Yamamoto T, Amano A. Coronary artery bypass revascularization using bilateral internal thoracic arteries in diabetic patients: a systematic review and meta-analysis. Ann Thorac Surg. 2015;99(3):1097-1104. doi: 10.1016/j.athoracsur.2014.09.045
48. Singh A, Schaff HV, Mori Brooks M, et al. On-pump versus off-pump coronary artery bypass graft surgery among patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Eur J Cardiothorac Surg. 2016;49(2):406-416. doi: 10.1093/ejcts/ezv170
49. Koochemeshki V, Salmanzadeh HR, Sayyadi H, et al. The Effect of Diabetes Mellitus on Short Term Mortality and Morbidity after Isolated Coronary Artery Bypass Grafting Surgery. Int Cardiovasc Res J. 2013;7(2):41-45.
50. Pivatto Júnior F, Pereira EMC, Valle FH, et al. Does diabetes mellitus increase immediate surgical risk in octogenarian patients submitted to coronary artery bypass graft surgery? Rev Bras Cir Cardiovasc. 2012;27(4):600-606. doi: 10.5935/1678-9741.20120102
51. Petursson P, Herlitz J, Lindqvist J, et al. Prevalence and severity of abnormal glucose regulation and its relation to long-term prognosis after coronary artery bypass grafting. Coron Artery Dis. 2013;24(7):577-582. doi: 10.1097/MCA.0b013e3283645c94
52. Nystrom T, Holzmann MJ, Sartipy U. Long-Term Risk of Stroke in Patients With Type 1 and Type 2 Diabetes Following Coronary Artery Bypass Grafting. J Am Heart Assoc. 2015;4(11). doi: 10.1161/JAHA.115.002411
53. Munnee K, Bundhun PK, Quan H, Tang Z. Comparing the Clinical Outcomes Between Insulin-treated and Non-insulin-treated Patients With Type 2 Diabetes Mellitus After Coronary Artery Bypass Surgery: A Systematic Review and Meta-analysis. Medicine (Baltimore). 2016;95(10):e3006. doi: 10.1097/MD.0000000000003006
Supplementary files
Review
For citations:
Bezdenezhnykh N.A., Sumin A.N. Myocardial revascularization in patients with coronary heart disease and type 2 diabetes. Diabetes mellitus. 2016;19(6):471-478. (In Russ.)
Views:
1735
Email this article 
